Our findings indicate that the expression levels of CSNK2B, MTERF3, and PGAM5 are elevated in multiple cancers, while the expression levels of PINK1 and PRKN are reduced in several cancers (Supplementary Figure 1A). Here, PRKN is linked to cancer.